Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy
BMC Cancer, 06/29/09
Kim HS et al. - The histologic subtype, and margin status were independently associated with OS, and adjuvant radiotherapy seems to confer survival benefit in low grade tumors. Prognostic model for primary liposarcoma demonstrated distinct three groups of patients with good prognostic discrimination.
Related Articles
Atypical lipomatous tumor/well-differentiated liposarcoma of the parotid gland: Case report and literature review
ENT Journal, 10/16/09
Relevance Score: 87%%
Carboxypeptidase M: a biomarker for the discrimination of well-differentiated liposarcoma from lipoma
Modern Pathology, 10/13/09
Relevance Score: 87%%
Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience
Annals of Surgical Oncology, 11/23/09
Relevance Score: 85%%
Liposarcoma or lipoma: Does genetics change classic imaging criteria
European Journal of Radiology, 10/26/09
Relevance Score: 83%%
Fine-needle aspiration in myxofibrosarcoma: Experience of Institut Curie
Diagnostic Cytopathology, 11/11/09
Relevance Score: 80%%
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Adding more content to screening: reactivation of FOXO as a therapeutic strategy
Clinical and Translational Oncology, 11/25/09
Today in Soft Tissue/Sarcoma...keeping you current
Receive free subspecialty "5-minute updates" via email
The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES)
Cancer, 11/25/09
Soft tissue tumors associated with EWSR1 translocation
Virchows Archiv, 11/25/09
Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas
Clinical Cancer Research, 11/20/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


